Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€14.38

€14.38

-1.370%
-0.2
-1.370%
-
 
05.06.25 / Tradegate WKN: A140ML / Name: Novocure / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...
Your prediction

Novocure Ltd Stock

A loss of -1.370% shows a downward development for Novocure Ltd.
For the coming years our community has positive and negative things to say abot the Novocure Ltd stock. Criterium "Shareholder structure" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.

Pros and Cons of Novocure Ltd in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Novocure Ltd vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Novocure Ltd -1.370% -15.709% -8.320% -32.425% -50.618% -80.688% -76.153%
Ironwood Pharmaceuticals -7.170% -0.935% -34.161% -91.092% -87.381% -94.877% -94.045%
Arrowhead Pharmaceuticals Inc. 2.400% -2.968% 12.868% -38.049% -22.222% -55.650% -52.312%
Iovance Biotherapeutics Inc. 8.320% -1.097% -49.186% -79.453% -77.275% -78.554% -94.360%

News

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting


Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society

Novocure Announces Upcoming Investor Events
Novocure Announces Upcoming Investor Events


Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.




  • PANOVA-3 Investor Event, May 31, 2025: Novocure will host investors on Saturday, May 31

Novocure Reports First Quarter 2025 Financial Results
Novocure Reports First Quarter 2025 Financial Results


Novocure (NASDAQ: NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive